Co-Amoxiclav Prescribing in Renal Impairment

Co-amoxiclav levels in bronchial mucosa.

Effects of Thymol on Co-amoxiclav-Induced Hepatotoxicity in Rats

Background and Aims: Hepatotoxicity induced by Co-amoxiclav has been indicated in multiple studies. Thymol is the main constituent of the Thymus vulgaris essential oil that has antioxidant properties. Even though thymol can exhibit antioxidant activity in vivo models, there is a lack of evidence about the thymol’s effectiveness in drug-induced liver injury. Thus, the present study was conducted...

Prescribing for older people with chronic renal impairment.

BACKGROUND Renal function is an important prescribing consideration. On average, glomerular filtration rate declines by about 10 mL/min every 10 years after the age of 40. Renal impairment may cause medicines to accumulate or cause toxicity, especially if the medicine has a narrow therapeutic index. OBJECTIVE To present an overview of prescribing considerations in the primary care setting for...

Co-amoxiclav in recurrent acute otitis media: placebo controlled study.

OBJECTIVE To determine the efficacy of coamoxiclav in children aged 6 months to 12 years with recurrent acute otitis media. DESIGN A randomised double blind placebo controlled clinical trial. SETTING General practice in the Netherlands. PATIENTS 121 children with recurrent acute otitis media, defined by onset of otalgia and otoscopic signs of middle ear infection within four to 52 weeks a...

Co-amoxiclav-induced Stevens Johnson Syndrome in a child

Stevens-Johnson syndrome is an uncommon life threatening disease generally induced by drugs. Antibiotics, mainly sulphonamides, are the most involved drugs in Stevens-Johnson syndrome in children. Co-amoxiclav is a well tolerated antibiotic. It has never been reported to cause, lonely this syndrome in children. Herein, we report a co-amoxiclav-induced Stevens-Johnson syndrome occurring in an 18...